Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Listing Requirement
NEW YORK, NY, March 1, 2023 — Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions” or the “Company”) (Nasdaq: INBS), a
NEW YORK, NY, March 1, 2023 — Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions” or the “Company”) (Nasdaq: INBS), a
513(g) submission will allow Intelligent Bio Solutions Inc. to determine the most suitable FDA regulatory pathway for its Intelligent Fingerprinting
Second quarter total revenue and government support income increased over 100% year-over-year Government support income increased 52% for the quarter
Boughey Distribution switches to Intelligent Fingerprinting for its faster end-to-end testing, non-invasive nature, and ability to conduct tests in-house NEW
Gardening Supplier, Hozelock, to Roll Out Hygienic and Non-Invasive Intelligent Fingerprinting for Drug Tests to Promote Employee Safety NEW YORK, January
NEW YORK, January 23, 2023 (GLOBE NEWSWIRE) – Intelligent Bio Solutions Inc. (“Intelligent Bio Solutions” or the “Company”) (Nasdaq: INBS), a
NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) – Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a life sciences company developing non-invasive,
Company Intends to Hold FY 2022 Annual Meeting in February 2023. NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) – Intelligent Bio
Acquired Intelligent Fingerprinting Limited and its proprietary drugs of abuse screening technology. Announced new additions to Board of Directors and
Eastern Airways to use portable, hygienic, non-invasive fingerprint sweat test to support new European Aviation Authority regulations NEW YORK, Nov.
Goldstar Transport to Remove Urine Testing for Sweat Based Technology New York, NY, October 31, 2022 – Intelligent Bio Solutions
GBS Inc. Initiates Company Name Change to Intelligent Bio Solutions Inc. (INBS) and Announces Key Executive Appointments Name change to
GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology The transaction further solidifies GBS’ leadership
The trial is single center, prospective study collecting coincident samples of oral fluids and blood to evaluate the time-course of
New York, NY, June 23, 2022 (GLOBE NEWSWIRE) – GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time